Last reviewed · How we verify
DTaP-IPV and ActHIB®
DTaP-IPV and ActHIB® is a Vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection in infants and children. Also known as: ActHIB®.
This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection in infants and children.
At a glance
| Generic name | DTaP-IPV and ActHIB® |
|---|---|
| Also known as | ActHIB® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
DTaP-IPV/ActHIB is a pentavalent vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigen, inactivated poliovirus, and Haemophilus influenzae type b conjugate. It works by presenting these antigens to the immune system, triggering both humoral and cellular immune responses that generate protective antibodies and memory cells against these five pathogens.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
- Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (PHASE3)
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP-IPV and ActHIB® CI brief — competitive landscape report
- DTaP-IPV and ActHIB® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about DTaP-IPV and ActHIB®
What is DTaP-IPV and ActHIB®?
How does DTaP-IPV and ActHIB® work?
What is DTaP-IPV and ActHIB® used for?
Who makes DTaP-IPV and ActHIB®?
Is DTaP-IPV and ActHIB® also known as anything else?
What drug class is DTaP-IPV and ActHIB® in?
What development phase is DTaP-IPV and ActHIB® in?
What are the side effects of DTaP-IPV and ActHIB®?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection in infants and children
- Also known as: ActHIB®
- Compare: DTaP-IPV and ActHIB® vs similar drugs
- Pricing: DTaP-IPV and ActHIB® cost, discount & access